Cancer therapies: How we link drug sensitivity to molecular profiling to identify biomarkers

Cancer therapies: How we link drug sensitivity to molecular profiling to identify biomarkers

23-03-2018

Professor Krister Wennerberg talks on stratified cancer therapies and their predictive biomarkers at the Oncology Network meeting April 9th.

Biopeople/Biomarkers as emerging growth area joins forces with Medicon Valley Alliance on April 9th and invites members to the MVA Oncology Networks 5th meeting covering the topic “Biomarkers – opportunities and challenges in oncology drug development”:  The keynote and scoop of the day is Professor Krister Wennerberg who will talk on “Systems medicine methods for identification of stratified cancer therapies and their predictive biomarkers".  “I will describe how we combine comprehensive drug sensitivity testing with molecular profiling on primary cancer cells to identify and understand stratified drug vulnerabilities and study how this information may translate to the patient. While the ex vivo drug responses can be seen as functional biomarkers, they are challenging to apply in clinical practice and I will describe how we link the drug sensitivity testing to molecular profiling information to identify predictive biomarkers," says Krister Wennerberg to the Biopeople NewsletterBIO:
From 2017, Krister Wennerberg works as Professor and Group Leader at Biotech Research & Innovation Centre (BRIC), University of Copenhagen. Krister Wennerberg Krister Wennerberg received his Ph.D. in biochemistry from Uppsala University, Sweden and had his postdoctoral training at the University of North Carolina at Chapel Hill, USA.  Following his postdoc, he worked as an R&D scientist at Cytoskeleton, Inc. and as an assay development group leader at Southern Research Institute in Birmingham, AL, USA. From 2010, he joined FIMM, Institute for Molecular Medicine Finland.Read more on the event

Close
What are you looking for?
By using this website, you agree to the use of Cookies to give you the best user experience.Ok